Blue Trust Inc. Increases Position in HUTCHMED (China) Limited (NASDAQ:HCM)

Blue Trust Inc. increased its stake in shares of HUTCHMED (China) Limited (NASDAQ:HCM) by 99.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,068 shares of the company’s stock after buying an additional 3,532 shares during the quarter. Blue Trust Inc.’s holdings in HUTCHMED were worth $102,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC acquired a new position in shares of HUTCHMED in the second quarter valued at approximately $213,000. China Universal Asset Management Co. Ltd. grew its position in HUTCHMED by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock valued at $117,000 after buying an additional 2,321 shares during the last quarter. M&G PLC increased its stake in HUTCHMED by 98.1% in the 3rd quarter. M&G PLC now owns 267,231 shares of the company’s stock valued at $5,345,000 after buying an additional 132,333 shares during the period. Crossmark Global Holdings Inc. purchased a new position in HUTCHMED during the 3rd quarter worth $328,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of HUTCHMED by 99.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company’s stock worth $952,000 after acquiring an additional 24,245 shares during the period. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Stock Up 0.6 %

Shares of NASDAQ HCM opened at $13.97 on Friday. The company’s fifty day moving average is $14.94 and its two-hundred day moving average is $17.26. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. HUTCHMED has a one year low of $13.00 and a one year high of $21.92.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.